Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1988 Oct 22;297(6655):1017–1021. doi: 10.1136/bmj.297.6655.1017

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

R S Ehsanullah 1, M C Page 1, G Tildesley 1, J R Wood 1
PMCID: PMC1834765  PMID: 3142593

Abstract

OBJECTIVE: To evaluate the prophylactic effect of ranitidine 150 mg twice daily in patients requiring one of the following non-steroidal anti-inflammatory drugs: naproxen, piroxicam, diclofenac, and indomethacin. In addition, risk factors were studied in order to help in targeting of such treatment to specific groups of patients. DESIGN: Double blind, placebo controlled, randomised, parallel group with endoscopic assessments at 0, 4, and 8 weeks. SETTING: Multicentre outpatient study at secondary referral centres in five European countries. PATIENTS--297 patients with rheumatoid arthritis or osteoarthritis over the age of 18 without lesions in the stomach and duodenum at baseline endoscopy (after one week without taking non-steroidal anti-inflammatory drugs). Those taking other antirheumatic agents, concomitant ulcerogenic drugs, or treatment for peptic ulcers within the previous 30 days were excluded. Age, sex, arthritic disease, and type of non-steroidal anti-inflammatory drug used were comparable in the two treatment groups. In all, 263 patients completed the trial. INTERVENTIONS: Ranitidine 150 mg twice daily or placebo (plus the selected non-steroidal anti-inflammatory drug) was prescribed within five days after the baseline endoscopy for two consecutive periods of four weeks. Paracetamol was permitted during the study, but not antacids. Patients were withdrawn if the most severe grade of damage (including ulceration) was found at the four week endoscopy or when indicated, or with lesser damage at the investigator's discretion. END POINT: Frequency of gastric and duodenal ulceration or lesions, or both. MEASUREMENTS AND MAIN RESULTS: The cumulative incidence of peptic ulceration by eight weeks was 10.3% (27/263); 2 out of 135 (1.5%) developed duodenal ulceration in the ranitidine group, compared with 10 out of 126 (8%) taking placebo. The frequency of gastric ulceration was the same (6%) for the two groups at eight weeks. Though significantly fewer gastric lesions developed in the ranitidine group by eight weeks. The frequency of non-ulcerative lesions in the duodenum did not differ greatly for the two groups at either time point. Twelve out of 75 (16%) patients taking piroxicam developed peptic ulceration, of whom two thirds had duodenal ulceration. Patients with a history of peptic ulcer were particularly susceptible to recurrent ulceration, against which ranitidine offered some protection. CONCLUSIONS: Ranitidine 150 mg twice daily significantly reduced the incidence of duodenal ulceration but not gastric ulceration when prescribed concomitantly with one of four commonly used non-steroidal anti-inflammatory drugs.

Full text

PDF
1017

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong C. P., Blower A. L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987 May;28(5):527–532. doi: 10.1136/gut.28.5.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armstrong C. P., Blower A. L. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 1987 Mar 21;294(6574):772–772. doi: 10.1136/bmj.294.6574.772-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baskin W. N., Ivey K. J., Krause W. J., Jeffrey G. E., Gemmell R. T. Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference. Ann Intern Med. 1976 Sep;85(3):299–303. doi: 10.7326/0003-4819-85-3-299. [DOI] [PubMed] [Google Scholar]
  4. Berkowitz J. M., Adler S. N., Sharp J. T., Warner C. W. Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine. J Clin Gastroenterol. 1986 Jun;8(3 Pt 2):377–380. doi: 10.1097/00004836-198606002-00009. [DOI] [PubMed] [Google Scholar]
  5. Berkowitz J. M., Rogenes P. R., Sharp J. T., Warner C. W. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med. 1987 Dec;147(12):2137–2139. [PubMed] [Google Scholar]
  6. Caruso I., Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. Br Med J. 1980 Jan 12;280(6207):75–78. doi: 10.1136/bmj.280.6207.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clinch D., Banerjee A. K., Levy D. W., Ostick G., Faragher E. B. Non-steroidal anti-inflammatory drugs and peptic ulceration. J R Coll Physicians Lond. 1987 Jul;21(3):183–187. [PMC free article] [PubMed] [Google Scholar]
  8. Cockel R. NSAIDs--should every prescription carry a government health warning? Gut. 1987 May;28(5):515–518. doi: 10.1136/gut.28.5.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coles L. S., Fries J. F., Kraines R. G., Roth S. H. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983 May;74(5):820–828. doi: 10.1016/0002-9343(83)91073-2. [DOI] [PubMed] [Google Scholar]
  10. Collier D. S., Pain J. A. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut. 1985 Apr;26(4):359–363. doi: 10.1136/gut.26.4.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Duggan J. M., Dobson A. J., Johnson H., Fahey P. Peptic ulcer and non-steroidal anti-inflammatory agents. Gut. 1986 Aug;27(8):929–933. doi: 10.1136/gut.27.8.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Eliakim R., Ophir M., Rachmilewitz D. Duodenal mucosal injury with nonsteroidal antiinflammatory drugs. J Clin Gastroenterol. 1987 Aug;9(4):395–399. doi: 10.1097/00004836-198708000-00008. [DOI] [PubMed] [Google Scholar]
  13. Fok K. H., George P. J., Vicary F. R. Peptic ulcers induced by piroxicam. Br Med J (Clin Res Ed) 1985 Jan 12;290(6462):117–117. doi: 10.1136/bmj.290.6462.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Graham D. Y., Smith J. L., Dobbs S. M. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci. 1983 Jan;28(1):1–6. doi: 10.1007/BF01393353. [DOI] [PubMed] [Google Scholar]
  15. Hawkey C. J., Prichard P. J., Somerville K. W. Strategies for preventing aspirin-induced gastric bleeding. Scand J Gastroenterol Suppl. 1986;125:170–173. doi: 10.3109/00365528609093834. [DOI] [PubMed] [Google Scholar]
  16. Henry D. A., Johnston A., Dobson A., Duggan J. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. Br Med J (Clin Res Ed) 1987 Nov 14;295(6608):1227–1229. doi: 10.1136/bmj.295.6608.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hoftiezer J. W., O'Laughlin J. C., Ivey K. J. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. Gut. 1982 Aug;23(8):692–697. doi: 10.1136/gut.23.8.692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hogan D. L., Thomas F. J., Isenberg J. I. Cimetidine decreases aspirin-induced gastric mucosal damage in humans. Aliment Pharmacol Ther. 1987 Oct;1(5):383–390. doi: 10.1111/j.1365-2036.1987.tb00638.x. [DOI] [PubMed] [Google Scholar]
  19. Husby G. The Norwegian multicenter study. Am J Med. 1986 Nov 28;81(5B):6–10. [PubMed] [Google Scholar]
  20. Inman W. H., Rawson N. S. Peptic ulcer and piroxicam. Br Med J (Clin Res Ed) 1985 Mar 23;290(6472):932–933. doi: 10.1136/bmj.290.6472.932-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jick S. S., Perera D. R., Walker A. M., Jick H. Non-steroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. Lancet. 1987 Aug 15;2(8555):380–382. doi: 10.1016/s0140-6736(87)92393-2. [DOI] [PubMed] [Google Scholar]
  22. Kimmey M. B., Silverstein F. E., Saunders D. R., Chapman R. C. Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine. Dig Dis Sci. 1987 Aug;32(8):851–856. doi: 10.1007/BF01296708. [DOI] [PubMed] [Google Scholar]
  23. Lanza F. L., Royer G. L., Jr, Nelson R. S., Chen T. T., Seckman C. E., Rack M. F. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol. 1981 Jan;75(1):17–21. [PubMed] [Google Scholar]
  24. Larkai E. N., Smith J. L., Lidsky M. D., Graham D. Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987 Nov;82(11):1153–1158. [PubMed] [Google Scholar]
  25. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med. 1974 May 23;290(21):1158–1162. doi: 10.1056/NEJM197405232902102. [DOI] [PubMed] [Google Scholar]
  26. Mellem H., Stave R., Myren J., Osnes M., Hanssen L. E., Mosvold J., Hebnes K. Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of non-steroid anti-inflammatory drugs. Scand J Gastroenterol. 1985 Dec;20(10):1246–1248. doi: 10.3109/00365528509089284. [DOI] [PubMed] [Google Scholar]
  27. Morris J. A., Gardner M. J. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988 May 7;296(6632):1313–1316. doi: 10.1136/bmj.296.6632.1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. O'Brien W. M. Pharmacology of nonsteroidal anti-inflammatory drugs. Practical review for clinicians. Am J Med. 1983 Oct 31;75(4B):32–39. doi: 10.1016/0002-9343(83)90326-1. [DOI] [PubMed] [Google Scholar]
  30. Peptic ulcers induced by piroxicam. Br Med J (Clin Res Ed) 1985 Mar 9;290(6470):789–789. doi: 10.1136/bmj.290.6470.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rees W. D., Turnberg L. A. Reappraisal of the effects of aspirin on the stomach. Lancet. 1980 Aug 23;2(8191):410–413. doi: 10.1016/s0140-6736(80)90452-3. [DOI] [PubMed] [Google Scholar]
  32. Rossi A. C., Hsu J. P., Faich G. A. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 1987 Jan 17;294(6565):147–150. doi: 10.1136/bmj.294.6565.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Roth S. H., Bennett R. E., Mitchell C. S., Hartman R. J. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation. Arch Intern Med. 1987 Oct;147(10):1798–1801. [PubMed] [Google Scholar]
  34. Silvoso G. R., Ivey K. J., Butt J. H., Lockard O. O., Holt S. D., Sisk C., Baskin W. N., Mackercher P. A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520. doi: 10.7326/0003-4819-91-4-517. [DOI] [PubMed] [Google Scholar]
  35. Somerville K., Faulkner G., Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986 Mar 1;1(8479):462–464. doi: 10.1016/s0140-6736(86)92927-2. [DOI] [PubMed] [Google Scholar]
  36. Walt R., Katschinski B., Logan R., Ashley J., Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet. 1986 Mar 1;1(8479):489–492. doi: 10.1016/s0140-6736(86)92940-5. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES